The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
According to the data, a statistically significant proportion of patients treated with 4mg of Olumiant (baricitinib) achieved resolution of their SLE-related arthritis or rash compared to placebo at week 24, thus meeting the primary endpoint of the trial.
Also, compared to placebo, treatment with the drug resulted in a statistically significantly greater proportion of patients with lower overall disease activity, a key secondary endpoint.
for full article click here.
